COMP <GO>
UTHR vs VTRS // FORWARD P/E MULTIPLE
United Therapeutics Corporation (NASDAQ) VS. Viatris Inc. (NASDAQ) • 15-METRIC TALLY: UTHR 10
— VTRS 2
▲ FORWARD P/E MULTIPLE LEADER: UTHR
LAST: $598.72 (+0.87%) • MKT CAP: $25.68B
forward-pe
17.8x
LAST: $19.04 (-0.86%) • MKT CAP: $21.86B
forward-pe
33.0x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (UTHR VS. VTRS)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | UTHR | VTRS | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 87.90% | 35.20% | +52.70 | UTHR | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 20.10% | -8.10% | +28.20 | UTHR | /roic <GO> |
| EV/EBITDA & P/E Valuation | 12.5x | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 4.09% | 8.78% | -4.69 | VTRS | /fcf-yield <GO> |
| Operating Margin | 46.90% | -18.70% | +65.60 | UTHR | /operating-margins <GO> |
| Net Profit Margin | 41.90% | -14.60% | +56.50 | UTHR | /net-margins <GO> |
| Revenue Growth (YoY) | 10.60% | -3.00% | +13.60 | UTHR | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 22.52 | 0.81 | +21.71 | UTHR | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 6/9 | +3.00 | UTHR | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 68.6 | 62.5 | +6.10 | UTHR | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.95 | 1.15 | -0.20 | VTRS | /macro-sensitivity <GO> |
| Forward P/E Multiple ACTIVE | 17.8x | 33.0x | -15.20 | UTHR | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $25.68B | $21.86B | $3.82B | UTHR | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | UTHR REV | VTRS REV | UTHR GROSS % | VTRS GROSS % | UTHR FCF | VTRS FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $3.18B | $14.25B | 87.9% | 35.2% | $1.04B | $1.94B |
| FY 2024 | $2.88B | $14.69B | 89.2% | 38.3% | $1.08B | $1.98B |
| FY 2023 | $2.33B | $15.39B | — | — | $873.3M | $2.21B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
UTHR // BETA 0.95
VTRS // BETA 1.15